Rasagiline
Active ingredient: Rasagiline Mesylate
In short: Rasagiline tablets are indicated for the treatment of Parkinson’s disease (PD).
What is Rasagiline used for?
Rasagiline tablets are indicated for the treatment of Parkinson’s disease (PD).
Rasagiline dosage
When rasagiline tablets are prescribed as monotherapy or as adjunct therapy in patients not taking levodopa, patients may start rasagiline tablets at the recommended dose of 1 mg administered orally once daily.
In patients taking levodopa, with or without other PD drugs (e.g., dopamine agonist, amantadine, anticholinergics), the recommended initial dose of rasagiline tablets is 0.5 mg once daily. If the patient tolerates the daily 0.5 mg dose, but a sufficient clinical response is not achieved, the dose may be increased to 1 mg once daily. When rasagiline tablets are used in combination with levodopa, a reduction of the levodopa dose may be considered, based upon individual response.
The recommended doses of rasagiline tablets should not be exceeded because of risk of hypertension .
Patients taking concomitant ciprofloxacin or other CYP1A2 inhibitors should not exceed a dose of rasagiline tablets 0.5 mg once daily .
Patients with mild hepatic impairment should not exceed a dose of rasagiline tablets 0.5 mg once daily. Rasagiline tablets should not be used in patients with moderate or severe hepatic impairment [see Warnings and Precautions (5.5), Use in Specific Populations (8.6), and Clinical Pharmacology (12.3)].
How to take Rasagiline — instructions & advice from the label
Hypertension: Advise patients that treatment with recommended doses of rasagiline tablets may be associated with elevations of blood pressure. Tell patients who experience elevation of blood pressure while taking rasagiline tablets to contact their healthcare provider.
The risk of using higher than recommended daily doses of rasagiline tablets should be explained, and a brief description of the tyramine associated hypertensive reaction provided.
Advise patients to avoid certain foods (e.g., aged cheese) containing a very large amount of tyramine while taking recommended doses of rasagiline tablets because of the potential for large increases in blood pressure. If patients eat foods very rich in tyramine and do not feel well soon after eating, they should contact their healthcare provider .
Serotonin Syndrome: Tell patients to inform their physician if they are taking, or planning to take, any prescription or over-the-counter drugs, especially antidepressants and over-the-counter cold medications, since there is a potential for interaction with rasagiline tablets. …
Warnings & precautions
Do not take this medicine if: Rasagiline tablets are contraindicated for use with meperidine, tramadol, methadone, propoxyphene, and MAO inhibitors (MAOIs), including other selective MAO-B inhibitors, because of risk of serotonin syndrome . At least 14 days should elapse between discontinuation of rasagiline tablets and initiation of treatment with these medications.
Rasagiline tablets are contraindicated for use with St. John’s wort and with cyclobenzaprine.
Rasagiline tablets are contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior.
Exacerbation of hypertension may occur during treatment with rasagiline tablets. Medication adjustment may be necessary if elevation of blood pressure is sustained. Monitor patients for new onset hypertension or hypertension that is not adequately controlled after starting rasagiline tablets.
In Study 3, rasagiline tablets (1 mg/day) given in conjunction with levodopa, produced an increased incidence of significant blood pressure elevation (systolic > 180 or diastolic > 100 mm Hg) of 4% compared to 3% for placebo .
When used as an adjunct to levodopa (Studies 3 and 4), the risk for developing post-treatment high blood pressure (e.g., systolic > 180 or diastolic >100 mm Hg) combined with a significant increase from baseline (e.g., systolic > 30 or diastolic > 20 mm Hg) was higher for rasagiline tablets (2%) compared to placebo (1%).
Dietary tyramine restriction is not required during treatment with recommended doses of rasagiline tablets. …
Rasagiline side effects
The following adverse reactions are described in more detail in the Warnings and Precautions section of the label:
•Hypertension
•Serotonin Syndrome
•Falling Asleep During Activities of Daily Living and Somnolence
•Hypotension / Orthostatic Hypotension
•Dyskinesia
•Hallucinations / Psychotic-Like Behavior
•Impulse Control / Compulsive Behaviors
•Withdrawal-Emergent Hyperpyrexia and Confusion
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the incidence of adverse reactions in the clinical trials of another drug and may not reflect the rates of adverse reactions observed in practice.
During the clinical development of rasagiline tablets, Parkinson’s disease patients received rasagiline tablets as initial monotherapy (Study 1) and as adjunct therapy (Study 2, Study 3, Study 4). As the populations in these studies differ, not only in the adjunct use of dopamine agonists or levodopa during rasagiline tablets treatment, but also in the severity and duration of their disease, the adverse reactions are presented separately for each study.
Monotherapy Use of Rasagiline Tablets:
In Study 1, approximately 5% of the 149 patients treated with rasagiline tablets discontinued treatment due to adverse reactions compared to 2% of the 151 patients who received placebo.
The only adverse reaction that led to the discontinuation of more than one patient was hallucinations. …
Drug interactions
Serious, sometimes fatal reactions have been precipitated with concomitant use of meperidine (e.g., Demerol® and other tradenames) and MAO inhibitors including selective MAO-B inhibitors .
The concomitant use of rasagiline tablets and dextromethorphan was not allowed in clinical studies. The combination of MAO inhibitors and dextromethorphan has been reported to cause brief episodes of psychosis or bizarre behavior. Therefore, in view of rasagiline tablets’ MAO inhibitory activity, dextromethorphan is contraindicated for use with rasagiline tablets .
Rasagiline tablets are contraindicated for use with other MAO inhibitors because of the increased risk of nonselective MAO inhibition that may lead to a hypertensive crisis .
The concomitant use of rasagiline tablets and sympathomimetic medications was not allowed in clinical studies. Severe hypertensive reactions have followed the administration of sympathomimetics and nonselective MAO inhibitors. Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline tablets and sympathomimetic medications. Severe hypertension has been reported in patients taking the recommended dose of rasagiline tablets and ophthalmic drops containing sympathomimetic medications. …
About this medicine
Rasagiline tablets contain rasagiline (as the mesylate), a propargylamine-based drug indicated for the treatment of idiopathic Parkinson’s disease. Rasagiline mesylate is designated chemically as: (R)-N-2-Propynyl-1-indanamine methanesulfonate. The molecular formula of rasagiline mesylate is C13H17NO3S and its molecular weight is 267.34.
Its structural formula is:
Rasagiline mesylate is white crystalline powder, freely soluble in methanol and soluble in water. Each rasagiline tablet for oral administration contains 0.5 mg or 1 mg of rasagiline (equivalent to 0.78 mg or 1.56 mg of rasagiline mesylate).
Each rasagiline tablet also contains the following inactive ingredients: citric acid anhydrous, colloidal silicon dioxide, croscarmellose sodium, microcrystalline cellulose, pregelatinized starch (maize) and stearic acid 50.
How it works: Rasagiline tablets are a selective, irreversible MAO-B inhibitor indicated for the treatment of idiopathic Parkinson’s disease. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 68cef20f-10c0-475e-af95-b7799355c7e9. Read the full official label on DailyMed.